article · Aspects of Molecular Medicine
Ultra-processed foods are linked to higher risks of cardiovascular diseases and cancer due to their nutritional composition and mechanistic effects. Characterised by high levels of unhealthy fats, sodium, refined sugars, and synthetic additives, these foods promote key risk factors including obesity, hypertension, and dyslipidemia. Ongoing intake leads to gut microbiota dysbiosis, systemic inflammation, oxidative stress, and endothelial dysfunction. Specific additives, such as sodium nitrites and artificial sweeteners, relate to cancer development via genotoxicity and inflammatory environments. In Western diets, ultra-processed products represent over half of daily calorie intake. Epidemiological data indicates that every ten per cent rise in ultra-processed food consumption increases both cardiovascular disease risk and cancer incidence by twelve per cent. Implementing dietary guidelines, regulatory policies, taxation, and nutritional labelling offers practical avenues to decrease consumption and lower the global disease burden.
Ultra-processed foods make up the majority of daily energy intake in certain diets, directly worsening long-term health outcomes. By clarifying how these foods drive major chronic illnesses like cancer and cardiovascular disorders, the findings provide clear targets for public health initiatives. Understanding these risks supports the adoption of evidence-based dietary advice, clearer food labelling, and regulatory interventions designed to lower the global burden of preventable disease.
The findings primarily inform public health policy, regulatory frameworks, and food manufacturing reform rather than ready-to-market commercial products. Food producers and regulatory bodies can use the mechanistic and risk data to guide product reformulation, front-of-pack nutritional labelling schemes, and taxation strategies. Because this work synthesises epidemiological and mechanistic evidence, real-world application requires translation into policy measures or reformulation programmes by food industry actors and health authorities.
AI-generated from the published abstract. Always read the original work before citing.
Ultra-processed foods (UPFs) are increasingly recognized as contributors to the pathogenesis of cardiovascular diseases (CVDs) and cancer due to their adverse compositional and mechanistic effects. UPFs, distinguished by their high content of unhealthy fats, sodium, refined sugars, and synthetic additives, significantly increase dyslipidemia, hypertension, and obesity, which are key risk factors for CVDs. Chronic consumption leads to systemic inflammation, gut microbiota dysbiosis, endothelial dysfunction, and oxidative stress. Additives such as artificial sweeteners and sodium nitrites in UPFs are associated with carcinogenesis through mechanisms involving genotoxicity and promotion of inflammatory microenvironments. This review critically evaluates existing epidemiological, mechanistic, and clinical evidence linking UPFs consumption to CVDs and cancer, synthesizing insights into their underlying pathophysiological mechanisms and highlighting disparities in disease burden across diverse populations. Epidemiological evidence demonstrates that UPFs constitute over 50% of daily caloric intake in Western diets, with each 10% increase in UPF consumption associated with a 12% rise in CVDs risk and a comparable increase in cancer incidence. Addressing the global surge in UPF consumption through dietary guidelines, regulatory policies, and public health initiatives may mitigate these risks, improve metabolic and cardiovascular health, and reduce cancer prevalence. • Ultra-processed foods (UPFs) are associated with increased risks of cardiovascular diseases and cancer. • Systemic inflammation and gut dysbiosis are key mechanisms linked to UPF intake. • Nutritional labeling and taxation policies reduce UPF consumption effectively. • Evidence suggests a 10% rise in UPF intake increases cardiovascular and cancer risks by 12%. • Public health interventions targeting UPFs can lower disease burden globally.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.amolm.2025.100072
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
